show episodes
 
Harry Glorikian is an investor and business expert at the convergence of health, life sciences, and IT. His books show how technology is transforming healthcare, from both the patient's point of view (The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer, 2021) and the industry insider's perspective (MoneyBall Medicine, 2017). He's also a natural at conversation. And here on the podcast, you'll hear Harry talking with the pioneers who are using ...
 
Loading …
show series
 
As we say here on The Harry Glorikian Show, technology is changing everything about healthcare works—and the reason we keep talking about it month after month is that the changes are coming much faster than they ever did in the past. Each leap in innovation enables an even bigger leap just one step down the road. Another way of saying this is that …
 
Genialis, led by CEO Rafael Rosengarten, is one of the companies working toward a future where there are no more one-size-fits-all drugs—where, instead, every patient gets matched with the best drug for them based on their disease subtype, as measured by gene-sequence and gene-expression data. Analyzing that data—what Rosengarten calls "computation…
 
When the coronavirus pandemic swept across the world in early 2020, Spain was one of the countries hardest hit. At the time, Nuria Oliver was a telecommunications engineer working and living in Valencia, one of Spain's 17 autonomous regions. She’d spent years working for companies like Microsoft, Telefonica, and Vodafone, using AI to analyze data f…
 
We've learned from previous guests that machine learning and other forms of AI are helping to identify better disease treatments, get drugs to market faster, and spot health problems before they get out of hand. But what if they could also help patients find the best doctors for them, and help doctors frame their advice in a way that patients can r…
 
Your medical records don't make pleasant bedtime reading. And not only are they inscrutable—they're often mutually (and deliberately) incompatible, meaning different hospitals and doctor's offices can't share them across institutional boundaries. Harry's guest this week, Ardy Arianpour, is trying to fix all that. He’s the co-founder and CEO of Seqs…
 
Chances are you or someone you love has had a biopsy to check for cancer. Doctors got a tissue sample and they sent it into a pathology lab, and at some point you got a result back. If you were lucky, it was negative and there was no cancer. But have you ever wondered exactly what happens in between those steps? Until recently, it’s been a meticulo…
 
Many of us wear wireless, battery-powered medical sensors on our wrists in the form of our smartwatches or fitness trackers. But someday soon, similar sensors may be woven into our very clothing. Harry's guest this week, Nanowear CEO Venk Varadan, explains that his company's microscopic nanosensors, when embedded in fabric and worn against the skin…
 
Today we bring you the second half of Harry's conversation with Dave deBronkart, better known as E-Patient Dave for all the work he’s done to help empower patients to be more involved in their own healthcare. If you missed Part 1 of our interview with Dave, we recommend that you check that out before listening to this one. In that part, we talked a…
 
The podcast is back with a new name and a new, expanded focus! Harry will soon be publishing his new book The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer. Like his previous book MoneyBall Medicine, it's all about AI and the other big technologies that are transforming healthcare. But this time Ha…
 
Harry's guest this week is Matthew Might, director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham. Might trained as a computer scientist, but a personal odyssey inspired him to make the switch into precision medicine. Now he uses computational tools such as knowledge graphs and natural language processing t…
 
This week Harry is joined by Kevin Davies, author of the 2020 book Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing. CRISPR—an acronym for Clustered Regularly Interspaced Short Palindromic Repeats—consists of DNA sequences that evolved to help bacteria recognize and defend against viral invaders, as a kind of primitive immu…
 
Harry traveled to the San Francisco Bay Area this summer, and while there he interviewed the co-founders of three local data-driven diagnostics and drug discovery startups, all of whom participated in the same graduate program: the Biomedical Informatics Program at Stanford's School of Medicine. Joining Harry were Aria Pharmaceuticals co-founder an…
 
Harry's guest this week is Jeff Elton, CEO of a Boston-based startup called Concert AI that's working to bring more "real-world data" and "real-world evidence" into the process of drug development. What's real-world data? It's everything about patients' health that's not included in the narrow outcomes measured by randomized, controlled clinical tr…
 
In a companion interview to his June 7 talk with Stanford's Michael Snyder, Harry speaks this week with Noosheen Hashemi, who—with Snyder—co-founded the personalized health startup January.ai in 2017. The company focuses on helping users understand how their bodies respond to different foods and activities, so they can make diet and exercise choice…
 
This week Harry sits down with Vangelis Vergetis, the co-founder and co-executive director of Intelligencia, a startup that uses big data and machine learning to help pharmaceutical companies make better decisions throughout the drug development process. Vergetis argues that if you put a group of pharma executives in a conference room, then add an …
 
From her TED talks and her appearances on PBS, geneticist Wendy Chung is known to millions of people as an expert on autism. But thanks to funding from the Simons Foundation, she’s also known to tens of thousands of people with autism and their families as the leader of history’s largest study of the genetics of autism spectrum disorder (ASD). It’s…
 
Having helped to bring big data to genomics through the lab techniques he invented, such as RNA-Seq, the Stanford molecular biologist Michael Snyder is focused today on how to use data from devices to increase the human healthspan. Some cars have as many as 400 sensors, Snyder notes. "And you can't imagine driving your car around without a dashboar…
 
Angeli Moeller is a molecular biologist, a neuroscientist, a systems biologist, and a data scientist all rolled into one—which makes her a perfect example of the kind of multidisciplinary executive needed for this new digital health ecosystem defined by big data, AI, and machine learning. She's a founding member of the Alliance for Artificial Intel…
 
The discoveries medical researchers and drug developers can make are constrained by the kinds of questions they can ask of their data. Unfortunately, when it comes to clinical trial data, or gene expression data, or population health data, it feels like you need a PhD in computer science just to know which questions are "askable" and how to frame t…
 
This week Harry speaks with Richard Fox, a computational biologist whose work at two life sciences startups, Inscripta and Infinome, is helping to automate and vastly scale up the process of engineering an organism's genome to evoke new functions or uncover important genetic pathways. With the discovery of the genetic scissors known as CRISPR-Cas9 …
 
Computers can interpret the text we type, and they’re getting better at understanding the words we speak. But they’re only starting to understanding the emotions we feel—whether that means anger, amusement, boredom, distraction, or anything else. This week Harry talks with Rana El Kaliouby, the CEO of a Boston-based company called Affectiva that’s …
 
Rapid and cheap DNA sequencing technology can tell us a lot about which genes a patient is carrying around, but it can't tell us when and where the instructions in those genes get carried out inside cells. Resolve Biosciences—headed by this week's guest, Jason Gammack—aims to solve that problem by scaling up a form of intracellular imaging it calls…
 
Pek Lum, co-founder, and CEO of Auransa believes that a lot fewer drugs would fail in Phase 2 clinical trials if they were tested on patients predisposed to respond. The problem is finding the sub-populations of likely high-responders in advance and matching them up with promising drug compounds. That’s Auransa's specialty. The Palo Alto, CA-based …
 
This week Harry talks with Matteo Franceschetti, founder and CEO of the Khosla Ventures-backed startup Eight Sleep. The company' smart mattress, called the Pod, is one of the latest (and largest) entries in the burgeoning market for home digital-health devices. The Pod is designed to counteract body heat and provide a surface that stays cool all ni…
 
Michael Geer is co-founder and CSO (Chief Strategy Officer) of Humanity Health, a London-based startup that's building an iPhone app and subscription service designed to help users slow or reverse their rate of aging. Geer's co-founder Pete Ward has described the app as like “Waze for maximizing health span," or years of healthy functioning. The Hu…
 
This week on MoneyBall Medicine, Harry takes a field trip (literally!) into farming and agriculture. His guests are Al Eisaian co-founder and CEO of crop intelligence IntelinAir, and the company’s director of machine learning, Jennifer Hobbs. Intelinair’s AGMRI platform uses customized computer vision and deep learning algorithms to sift through te…
 
What if there were a single company that could connect hospital electronic health record systems to a massive genomic testing and analytics platform? It would be a little like Amazon Web Services (AWS) for healthcare—an enabling platform for anyone who wants to deploy precision medicine at scale. That's exactly what Joel Dudley says he's now helpin…
 
This week Harry catches up with Christine Lemke from Evidation Health, a startup in San Mateo, CA, that helps drug developers and other organizations analyze the effectiveness of smart devices and wearables in new types of therapies. Lemke is Evidation's co-CEO. Our Fitbits and Apple Watches are with us so much of the time that the data they collec…
 
Thomas Chittenden, chief data science officer at Genuity Science, says what's keeping the genomics revolution from turning into an equivalent revolution in drug discovery is that most of our domain knowledge about the molecular biology of disease has come from a hunt-and-peck approach, focused on one gene at a time. Find some gene relevant to a dis…
 
This week Harry interviews the head of Etiometry, a Boston-based startup building visualization systems and decision support software for hospital intensive care units. Shane Cooke says critical care "is an incredibly complex environment where speed matters and information matters." By aggregating real-time data, lab results, and historical patient…
 
Charles Fisher is the founder and CEO at Unlearn, a San Francisco company using purpose-built machine learning algorithms that use historical clinical trial data to create "digital twins" of actual participants in controlled drug trials to help predict how each participant would have fared if they'd been given a placebo. By comparing a patient's ac…
 
What if all our everyday assumptions about economics are wrong? This week Harry speaks with author and entrepreneur Jeff Booth, who says the most powerful force for change in the future will be deflation: getting more for less. Even the healthcare industry will feel the effects, he says. Listen to find out how. Booth is the author of The Price of T…
 
How does an expert in pharmacokinetics, whose only exposure to computers was taking one semester of programming in college to meet a language requirement, become an advocate for the new AI-driven style of drug discovery? This week Harry finds out from Mark Eller, who helped to invent Allegra at Hoechst Marion Roussel (now Sanofi), spent 12 years at…
 
Harry welcomes back Andrew A. Radin, CEO of the drug discovery startup twoXAR, where scientists model pathogenesis computationally to identify potential drug molecules, ideally shaving years off the drug development process. Harry first spoke with Radin two years ago at the AI Applications Summit—Biopharma. (Listen back to MoneyBall Medicine Episod…
 
In this week's show Harry interviews Rayid Ghani, a computer scientist at Carnegie Mellon University who studies how to use AI and data science to model and influence people's behavior in realms like politics, healthcare, education, and criminal justice. Ghani tell Harry he grew up hating coding, since the very need for it showed that "computers ar…
 
This week Harry speaks with Oura Health CEO Harpreet Rai, who's leading an effort to explore how a wearable sleep-monitoring device—the Oura Ring—can pick up patterns that may help diagnose covid-19 infections and other problems. The ring is equipped with sensors that measure heart rate and body temperature, as well as a tiny Bluetooth radio that s…
 
David Sable got his start in reproductive medicine in the late 1980s, a time when he says fertility treatments were "very primitive." But by the mid-2000s, he says, new procedures and new insights into the genetics of development had changed everything. His subsequent time observing (and investing in) the field has convinced him that reproductive m…
 
This week Harry speaks with molecular geneticist Elli Papaemmanuil about how newly available genomic data could lead to major improvements in the standard of care for cancer patients, leading to an age of true precision medicine. Papaemmanuil is an assistant professor of computational oncology at Memorial Sloan Kettering Cancer Center in New York. …
 
This week Harry interviews Gregory Bowman, an associate professor in the department of biochemistry and molecular biophysics in the School of Medicine at Washington University in St. Louis. Bowman is the current director of Folding@home, a distributed computing project currently focused on analyzing the structures of coronavirus proteins to find ta…
 
Harry's guest this week is the founder and CEO of a New Zealand firm, SaferMe, that had developed proximity-based smartphone apps for worker safety. When the coronavirus came along, their apps turned out to be a great way to help companies build their own "contact tables" to identify, test, and isolate SARS-CoV-2 carriers. In epidemiology, contact …
 
Though the p-value "determines everything we do in drug development or medical research," says Dr. Ulo Palm , it may be one of the most misunderstood and misused quantities in experimental science—drug discovery included. At its core, the p-value shows the probability that an observed effect was due to random chance. In other words, if a drug seems…
 
Building on his March 2020 interview with Jake Glanville, the founding partner and CEO of South San Francisco-based computational antibody engineering startup Distributed Bio, Harry speaks with three company scientists in the trenches: JP Buerckert, director of computational immunology, and Shahrad Daraekia and Jack Wang, both senior scientists. To…
 
If you've seen the recent Netflix docu-series "Pandemic," about efforts to check previous viral outbreaks, you've seen former Pfizer scientist Jacob Glanville in action. The inventor, entrepreneur, and Ph.D. immunologist capitalized on the advent of cloud computing to provide vaccine and drug developers with high-throughput genomic sequencing of an…
 
Schrödinger makes software that models the physics of atomic-scale interactions to predict the chemical properties of candidate drug molecules, helping its customers speed up drug discovery. A decade ago, Farid tells Harry, the company faced the chicken-and-egg challenge of convincing customers that its computational platform works, so that they wo…
 
Rapid sequencing of viral genomes is giving physicians and epidemiologists new ways to identify, track, and potentially slow outbreaks of viral infections such as the novel Wuhan coronavirus. That means high-throughput genome sequencing—which had predominantly been a research tool—is taking its place as a front-line weapon in the fight to prevent p…
 
Doctors helping couples conceive through in-vitro fertilization typically must screen multiple fertilized embryos to select one embryo for implantation—but the process is fraught with risk and subjectivity. from In 2018 Gilboa and her colleagues Daniel Seidman and Eyal Schiff co-founded AIVF, an Israel-based startup developing decision support tool…
 
Tom Davenport knows analytics, big data, and AI—he teaches executive courses on the subject at Babson College, Harvard Business School, the Harvard School of Public Health, and the MIT Sloan School of Management, and is widely known for his books on analytics and AI in business, Competing on Analytics (2007), Only Humans Need Apply (2016), and The …
 
Milind Kamkolkar joined Cellarity in January 2019 to help the company to prove that it is now possible to "encode a cell" digitally—to use big data, deep learning, and other methods to model many different interconnected networks of molecular interactions. "The whole idea...is really only feasible now," he says. "What changed over the last number o…
 
Dr. Alan Copperman is director of the Division of Reproductive Endocrinology and Infertility and Vice Chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at the Mount Sinai Health System. He's also a clinical professor of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai; medi…
 
Gini Desphande says she likes to think of "AI" as augmented intelligence rather than artificial intelligence: a system of human plus machine intelligence that can speed up drug development and cut R&D costs and failure rates in clinical trials. AI "really isn't at the point where it's automatable," she says. "We still need a lot of human intelligen…
 
Loading …

Quick Reference Guide

Copyright 2022 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login